Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).

Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201). Clin Cancer Res. 2020 02 15; 26(4):804-811.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Anilides
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Dacarbazine
Female
Humans
Male
Melanoma
Middle Aged
Mutation
Neoplasm Metastasis
Pyridines
Receptor Protein-Tyrosine Kinases
Uveal Neoplasms

authors with profiles

Timothy Carll